Clinical characteristics of the R-CHOP-treated DLBCL study cohort
| Characteristic . | DLBCL study R-CHOP-treated cohort n = 139 . | DLBCL BCCA R-CHOP-treated population N = 554 . | P . |
|---|---|---|---|
| Males, n (%) | 86 (62) | 356 (64) | .671 |
| Age >60 y, n (%) | 83 (60) | 324 (59) | .868 |
| Stage III/IV, n (%) | 75 (54) − 6 N/A | 325 (59) | .704 |
| Performance status >1, n (%) | 41 (32) − 9 N/A | 185 (33) | .763 |
| Extranodal sites >1, n (%) | 17 (13) − 10 N/A | 151 (27) | <.001 |
| LDH high, n (%) | 56 (50) − 27 N/A | 269 (49) | .861 |
| IPI ≥3 (high risk), n (%) | 46 (41) − 27 N/A | 236 (43) | .765 |
| Outcome | |||
| Median follow-up, y (range) | 5.11 (0.09-11.05) | 7.69 (0.1-13.21) | |
| OS (5 y) | 72% | 69% | .630 |
| PFS (5 y) | 68% | 63% | .243 |
| DSS (5 y) | 75% | 73% | .899 |
| Characteristic . | DLBCL study R-CHOP-treated cohort n = 139 . | DLBCL BCCA R-CHOP-treated population N = 554 . | P . |
|---|---|---|---|
| Males, n (%) | 86 (62) | 356 (64) | .671 |
| Age >60 y, n (%) | 83 (60) | 324 (59) | .868 |
| Stage III/IV, n (%) | 75 (54) − 6 N/A | 325 (59) | .704 |
| Performance status >1, n (%) | 41 (32) − 9 N/A | 185 (33) | .763 |
| Extranodal sites >1, n (%) | 17 (13) − 10 N/A | 151 (27) | <.001 |
| LDH high, n (%) | 56 (50) − 27 N/A | 269 (49) | .861 |
| IPI ≥3 (high risk), n (%) | 46 (41) − 27 N/A | 236 (43) | .765 |
| Outcome | |||
| Median follow-up, y (range) | 5.11 (0.09-11.05) | 7.69 (0.1-13.21) | |
| OS (5 y) | 72% | 69% | .630 |
| PFS (5 y) | 68% | 63% | .243 |
| DSS (5 y) | 75% | 73% | .899 |
DSS, disease-specific survival; LDH, lactate dehydrogenase; N/A, not available; PFS, progression-free survival.